All products for:Antibiotic Susceptibility Testing Antimicrobial Resistance Management Identification VITEK® 2 VITEK® MS Microbiology Healthcare-Associated Infections Bacterial infections Lab Efficiency MDRO Resistance detection Sepsis Sexually Transmitted Diseases Urinary Tract infections

ETEST^® Ceftazidime/Avibactam (CZA 256)

Test strip for MIC determination of ceftazidime/avibactam

NEW test strips provide Minimum Inhibitory Concentration (MIC) level for antimicrobial susceptibility of Gram-negative bacteria such as Enterobacteriaceae and P. aeruginosa. This information helps support appropriate antimicrobial therapy decisions for better patient outcomes and contributes to antimicrobial stewardship.

Reliably monitor susceptibility to ceftazidime/ avibactam (Avycaz**/ Zavicefta***)
Antimicrobial susceptibility determination in as little as 16 hours
Determines exact MIC values

Add to your selection

Do you need more information?

OVERVIEW
TECHNICAL DETAILS

Antimicrobial resistance: Why responsible treatment is critical

Antimicrobial resistance is one of today’s top healthcare concerns worldwide. With the development of Multi-drug Resistant Organisms (MDRO), particularly Gram-negative bacteria, even infections that were once easy to treat can be life-threatening¹. Antimicrobial stewardship – appropriate selection and use of antimicrobials – helps improve patient outcomes, prevent resistance development and preserve the effectiveness of new antimicrobials like the ceftazidime/avibactam combination drug. In this context, it’s important for clinicians to have clear and reliable information to make the best decisions for antibiotic therapy – before, during and after treatment. A key part of this is accurate and rapid antimicrobial susceptibility testing – for ceftazidime/avibactam, there’s now ETEST^® Ceftazidime/Avibactam (CZA 256).

How can ETEST^® CZA 256 strips help?

ETEST^® Ceftazidime/Avibactam (CZA 256) strips determine exact Minimum Inhibitory Concentration (MIC) values to assess susceptibility to ceftazidime/avibactam, a new treatment developed to treat some serious infections for which few effective therapies exist^1,2,3. Known by the trade name Avycaz** in the U.S. and Zavicefta*** elsewhere, ceftazidime/avibactam acts on Gram-negative bacteria and is indicated for complicated intra-abdominal infections (cIAI) in combination with metronidazole, as well as for the treatment of complicated urinary tract infections (cUTI), including acute pyelonephritis (AP), in patients over 18. Zavicefta is also approved for hospital-acquired pneumonia including ventilator associated pneumonia outside of the United States.

Exact MICs: Real precision in ETEST^® CZA 256

Thanks to the determination of exact MIC values, ETEST^® CZA 256 strips offer greater precision than conventional two-fold dilutions (i.e. half dilutions) with interpretive category (S, I, R). In as little as 16 hours incubation, you can determine how susceptible the organism is, not just if it is susceptible. This information helps clinicians make informed patient-care decisions for ceftazidime/avibactam therapy and reduce the risk of development of drug-resistant bacteria. Epidemiological tracking of evolution of infectious organisms is also possible with MIC values, helping detect emergence of resistance over time.

ETEST^®: Easy, effective and precise

The new ETEST^® CZA 256 strips are the latest addition to the ETEST^® range – the original gradient strips – which are widely documented for their effectiveness and precision.

Comprised of a MIC reading scale and an antibiotic gradient, ETEST^® strips are processed in a similar manner to diffusion methods. They differ in that the antimicrobial concentration gradient is preformed, predefined and stable, and not dependent on diffusion. On an inoculated agar surface, the antibiotic gradient forms a stable, continuous and exponential gradient of antibiotic concentration. Bacteria grow under the strip, forming an ellipse on the scale, on which you can read the MIC value. Over 90 antimicrobial references are available in the ETEST^® range, for easy, effective and precise testing for antibiotics and antifungals, as well as for antimicrobial resistance detection (ARD).

Sources:

1. Mosley, J.F. et. al. Ceftazidime-Avibactam (Avycaz) For the Treatment of Complicated Intra-Abdominal and Urinary Tract Infections. Pharmacy & Therapeutics. 41(8): 479–483. 2016 Aug.

2. Nicolau, D.P. Focus on ceftazidime-avibactam for optimizing outcomes in complicated intra-abdominal and urinary tract infections. Expert Opin Investig Drugs. 2015;24(9):1261-73.. Epub 2015 Jul 6.

3. Carmeli, Y. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study. Lancet Infect Dis. 2016 Jun; Epub 2016 Apr 20.

*CE-IVD marked; FDA pending

**Allergan

***Astra Zeneca/Pfizer